1. Cochrane review links drug-company gifts, meals and payments to less appropriate prescribing
A Cochrane systematic review of 93 mostly observational, mostly U.S. studies found that gifts and payments to prescribers were linked to less appropriate prescribing and more prescriptions, and probably to higher costs [1][2]. Industry-paid meals showed a dose-response pattern across several drug classes. Robust conflict-of-interest policies probably improved prescribing [1][3]. Full analysis in today's lead article.
2. FDA flags four deaths in Newron's evenamide schizophrenia program
Newron disclosed on Oct. 8 that the FDA cited four deaths among evenamide-treated patients across all studies, versus one on placebo. The FDA treats them as a potential safety signal because a fatal arrhythmia mechanism could not be ruled out [4][5]. Investigators judged three deaths unrelated and one possibly related. The U.S. clinical hold on the Phase 3 ENIGMA-TRS 2 trial stays in place, while enrollment continues abroad [4][5]. Newron says its data show no pattern of cardiac abnormalities and plans to respond to the FDA [4].
3. U.S. measles cases pass 4,000; CDC sends states about $100 million
The CDC counted 4,080 confirmed measles cases in 2026 as of Oct. 8, across 42 outbreaks, with two deaths on its national tally [6]. Pennsylvania accounts for more than a quarter of cases, and the state has reported five measles-associated deaths [7]. The New York Times reported that the CDC sent states roughly $100 million in recent weeks for vaccination, testing and surveillance [7][8].
4. Optogenetic gene therapy restores some light sensitivity in advanced retinitis pigmentosa (NEJM)
In a 10-patient study published in the New England Journal of Medicine, each patient received a single injection of a light-sensitive protein (ChrimsonR) into the worse-seeing eye. Patients then used camera goggles that convert scenes into amber light pulses [9][10]. Seven of 10 became more light-sensitive, and six met a predefined threshold for clinically meaningful improvement. Four of eight who completed behavioral tests improved at detecting or locating objects [9][10]. Safety was the primary endpoint and most eye-related adverse events were mild or moderate. Patients could not read or recognize faces. GenSight Biologics funded and took part in the study [9].
Digest references
Parkinson M. "Pharmaceutical company marketing negatively influences prescribing." Cochrane (news), Oct. 9, 2026. Link (review DOI: 10.1002/14651858.CD013423.pub3)
Taylor NP. "Pharma's free lunches for clinicians bloat prescription bills: Cochrane review." Fierce Pharma, Oct. 9, 2026. Link
Phelan M. "Free meals and other perks from Big Pharma really do sway doctors, review finds." Gizmodo, Oct. 9, 2026. Link
Newron Pharmaceuticals. "Newron provides update on FDA clinical hold and Phase 3 ENIGMA-TRS development program" (press release). Oct. 8, 2026. Link
Reuters. "US FDA flags four deaths in Newron's schizophrenia drug studies" (via KSL.com). Oct. 8, 2026. Link
Centers for Disease Control and Prevention. "Measles cases and outbreaks." Updated Oct. 9, 2026. Link
Dall C. "With Pennsylvania leading the way, US measles cases top 4,000." CIDRAP News, Oct. 2026. Link
Mandavilli A, Blum D. "CDC offers states $100M to combat measles outbreak." The New York Times (via The Columbian), Oct. 10, 2026. Link
Institute of Molecular and Clinical Ophthalmology Basel. "Optogenetic therapy is safe and allows blind people to detect objects." EurekAlert!, Oct. 7, 2026. Link. Study: Sahel J-A, et al. "Optogenetic Therapy for Restoring Aspects of Visual Function." N Engl J Med, 2026. DOI: 10.1056/NEJMoa2602215. Link
News-Medical. "Optogenetic therapy improves light sensitivity in people with retinitis pigmentosa." Oct. 7, 2026. Link
